Should biologic agents be stopped before surgery for inflammatory bowel disease?
暂无分享,去创建一个
[1] S. Targan,et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. , 2015, Annals of surgery.
[2] U. Ali,et al. Impact of Preoperative Immunosuppressive Agents on Postoperative Outcomes in Crohn’s Disease , 2014, Diseases of the colon and rectum.
[3] D. Fan,et al. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. , 2014, International journal of surgery.
[4] O. Zmora,et al. Anti‐tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.
[5] Zhiping Yang,et al. Meta‐analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery , 2012, Alimentary pharmacology & therapeutics.
[6] W. Sandborn,et al. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] M. Silverberg,et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease , 2012, Gut.
[8] J. Becker,et al. Preoperative Infliximab is not Associated with an Increased Risk of Short-Term Postoperative Complications After Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis , 2011, Journal of Gastrointestinal Surgery.
[9] S. Finlayson,et al. Trends in Surgery for Crohn's Disease in the Era of Infliximab , 2008, Annals of Surgery.
[10] Malfertheiner,et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.
[11] P. Rutgeerts,et al. Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.
[12] M. Esteve,et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention , 2009, European Journal of Clinical Microbiology & Infectious Diseases.
[13] J. Korzenik,et al. Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications , 2008, Journal of Gastrointestinal Surgery.
[14] J. Church,et al. Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients , 2008, Journal of Gastrointestinal Surgery.
[15] F. Remzi,et al. Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy , 2008, Diseases of the colon and rectum.
[16] G. Lichtenstein. Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis? , 2008 .
[17] W. Harmsen,et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. , 2007, Journal of the American College of Surgeons.
[18] M. Regueiro,et al. Infliximab for Hospitalized Patients With Severe Ulcerative Colitis , 2006, Journal of clinical gastroenterology.
[19] W. Harmsen,et al. Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy , 2004, American Journal of Gastroenterology.
[20] P. Rutgeerts,et al. The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study , 2004, Alimentary pharmacology & therapeutics.
[21] L. Moldawer,et al. Inhibition of tumor necrosis factor‐α attenuates wound breaking strength in rats , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[22] T. Ulich,et al. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. , 1987, Journal of immunology.
[23] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.
[24] C. FordAlexander,et al. ULCERATIVE colitis. , 1997, Journal of the American Medical Association.